Daniel Perkins

Daniel Perkins is a clinical researcher active in contemporary psychedelic science with a primary focus on ayahuasca and related tryptamine/harmala alkaloid formulations. The available publication record attributes several large international, cross-sectional surveys to Perkins that investigate adverse effects, the role of context and setting, and associations between ayahuasca consumption and current alcohol and other drug use. This body of work emphasises epidemiological and naturalistic approaches to understanding mental health and wellbeing outcomes among ayahuasca drinkers.

In addition to survey-based research, Perkins is associated with studies that probe mechanistic and translational aspects of psychedelic therapy, including work linking changes in inflammatory biomarkers to the purported antidepressant effects of ayahuasca, and an exploratory clinical study of oral Acacia-based DMT and harmala alkaloid formulations in healthy volunteers. Collectively, these contributions address safety, contextual moderators of outcome, and preliminary biological substrates relevant to therapeutic mechanisms. Affiliations and a full given name were not provided in the available dataset.